Accessibility Statement Skip Navigation
  • Resources
  • Investor Relations
  • Journalists
  • Agencies
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
Search
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News Releases view all

    • News in Focus
        • Browse News Releases

        • All News Releases
        • All Public Company
        • English-only
        • News Releases Overview

        • Multimedia Gallery

        • All Multimedia
        • All Photos
        • All Videos
        • Multimedia Gallery Overview

        • Trending Topics

        • All Trending Topics
    • Business & Money
        • Auto & Transportation

        • Aerospace, Defense
        • Air Freight
        • Airlines & Aviation
        • Automotive
        • Maritime & Shipbuilding
        • Railroads and Intermodal Transportation
        • Supply Chain/Logistics
        • Transportation, Trucking & Railroad
        • Travel
        • Trucking and Road Transportation
        • Auto & Transportation Overview

        • View All Auto & Transportation

        • Business Technology

        • Blockchain
        • Broadcast Tech
        • Computer & Electronics
        • Computer Hardware
        • Computer Software
        • Data Analytics
        • Electronic Commerce
        • Electronic Components
        • Electronic Design Automation
        • Financial Technology
        • High Tech Security
        • Internet Technology
        • Nanotechnology
        • Networks
        • Peripherals
        • Semiconductors
        • Business Technology Overview

        • View All Business Technology

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film and Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • Entertainment & Media Overview

        • View All Entertain­ment & Media

        • Financial Services & Investing

        • Accounting News & Issues
        • Acquisitions, Mergers and Takeovers
        • Banking & Financial Services
        • Bankruptcy
        • Bond & Stock Ratings
        • Conference Call Announcements
        • Contracts
        • Cryptocurrency
        • Dividends
        • Earnings
        • Earnings Forecasts & Projections
        • Financing Agreements
        • Insurance
        • Investments Opinions
        • Joint Ventures
        • Mutual Funds
        • Private Placement
        • Real Estate
        • Restructuring & Recapitalization
        • Sales Reports
        • Shareholder Activism
        • Shareholder Meetings
        • Stock Offering
        • Stock Split
        • Venture Capital
        • Financial Services & Investing Overview

        • View All Financial Services & Investing

        • General Business

        • Awards
        • Commercial Real Estate
        • Corporate Expansion
        • Earnings
        • Environmental, Social and Governance (ESG)
        • Human Resource & Workforce Management
        • Licensing
        • New Products & Services
        • Obituaries
        • Outsourcing Businesses
        • Overseas Real Estate (non-US)
        • Personnel Announcements
        • Real Estate Transactions
        • Residential Real Estate
        • Small Business Services
        • Socially Responsible Investing
        • Surveys, Polls and Research
        • Trade Show News
        • General Business Overview

        • View All General Business

    • Science & Tech
        • Consumer Technology

        • Artificial Intelligence
        • Blockchain
        • Cloud Computing/Internet of Things
        • Computer Electronics
        • Computer Hardware
        • Computer Software
        • Consumer Electronics
        • Cryptocurrency
        • Data Analytics
        • Electronic Commerce
        • Electronic Gaming
        • Financial Technology
        • Mobile Entertainment
        • Multimedia & Internet
        • Peripherals
        • Social Media
        • STEM (Science, Tech, Engineering, Math)
        • Supply Chain/Logistics
        • Wireless Communications
        • Consumer Technology Overview

        • View All Consumer Technology

        • Energy & Natural Resources

        • Alternative Energies
        • Chemical
        • Electrical Utilities
        • Gas
        • General Manufacturing
        • Mining
        • Mining & Metals
        • Oil & Energy
        • Oil and Gas Discoveries
        • Utilities
        • Water Utilities
        • Energy & Natural Resources Overview

        • View All Energy & Natural Resources

        • Environ­ment

        • Conservation & Recycling
        • Environmental Issues
        • Environmental Policy
        • Environmental Products & Services
        • Green Technology
        • Natural Disasters
        • Environment Overview

        • View All Environ­ment

        • Heavy Industry & Manufacturing

        • Aerospace & Defense
        • Agriculture
        • Chemical
        • Construction & Building
        • General Manufacturing
        • HVAC (Heating, Ventilation and Air-Conditioning)
        • Machinery
        • Machine Tools, Metalworking and Metallurgy
        • Mining
        • Mining & Metals
        • Paper, Forest Products & Containers
        • Precious Metals
        • Textiles
        • Tobacco
        • Heavy Industry & Manufacturing Overview

        • View All Heavy Industry & Manufacturing

        • Telecomm­unications

        • Carriers and Services
        • Mobile Entertainment
        • Networks
        • Peripherals
        • Telecommunications Equipment
        • Telecommunications Industry
        • VoIP (Voice over Internet Protocol)
        • Wireless Communications
        • Telecommunications Overview

        • View All Telecomm­unications

    • Lifestyle & Health
        • Consumer Products & Retail

        • Animals & Pets
        • Beers, Wines and Spirits
        • Beverages
        • Bridal Services
        • Cannabis
        • Cosmetics and Personal Care
        • Fashion
        • Food & Beverages
        • Furniture and Furnishings
        • Home Improvement
        • Household, Consumer & Cosmetics
        • Household Products
        • Jewelry
        • Non-Alcoholic Beverages
        • Office Products
        • Organic Food
        • Product Recalls
        • Restaurants
        • Retail
        • Supermarkets
        • Toys
        • Consumer Products & Retail Overview

        • View All Consumer Products & Retail

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film and Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • Entertainment & Media Overview

        • View All Entertain­ment & Media

        • Health

        • Biometrics
        • Biotechnology
        • Clinical Trials & Medical Discoveries
        • Dentistry
        • FDA Approval
        • Fitness/Wellness
        • Health Care & Hospitals
        • Health Insurance
        • Infection Control
        • International Medical Approval
        • Medical Equipment
        • Medical Pharmaceuticals
        • Mental Health
        • Pharmaceuticals
        • Supplementary Medicine
        • Health Overview

        • View All Health

        • Sports

        • General Sports
        • Outdoors, Camping & Hiking
        • Sporting Events
        • Sports Equipment & Accessories
        • Sports Overview

        • View All Sports

        • Travel

        • Amusement Parks and Tourist Attractions
        • Gambling & Casinos
        • Hotels and Resorts
        • Leisure & Tourism
        • Outdoors, Camping & Hiking
        • Passenger Aviation
        • Travel Industry
        • Travel Overview

        • View All Travel

    • Policy & Public Interest
        • Policy & Public Interest

        • Advocacy Group Opinion
        • Animal Welfare
        • Congressional & Presidential Campaigns
        • Corporate Social Responsibility
        • Domestic Policy
        • Economic News, Trends, Analysis
        • Education
        • Environmental
        • European Government
        • FDA Approval
        • Federal and State Legislation
        • Federal Executive Branch & Agency
        • Foreign Policy & International Affairs
        • Homeland Security
        • Labor & Union
        • Legal Issues
        • Natural Disasters
        • Not For Profit
        • Patent Law
        • Public Safety
        • Trade Policy
        • U.S. State Policy
        • Policy & Public Interest Overview

        • View All Policy & Public Interest

    • People & Culture
        • People & Culture

        • Aboriginal, First Nations & Native American
        • African American
        • Asian American
        • Children
        • Diversity, Equity & Inclusion
        • Hispanic
        • Lesbian, Gay & Bisexual
        • Men's Interest
        • People with Disabilities
        • Religion
        • Senior Citizens
        • Veterans
        • Women
        • People & Culture Overview

        • View All People & Culture

    • Explore Our Platform
    • Plan Campaigns
    • Create with AI
    • Distribute Press Releases
    • Report Results
    • Amplify Content
    • All Products
    • General Inquiries
    • Editorial Bureaus
    • Partnerships
    • Media Inquiries
    • Worldwide Offices
    • Hamburger menu
    • PR Newswire: news distribution, targeting and monitoring
    • Send a Release
      • ALL CONTACT INFO
      • Contact Us

        888-776-0942
        from 8 AM - 10 PM ET

    • Searching for your content...

      No results found. Please change your search terms and try again.

      News Releases

      view all
      Close menu
    • News
    • Products
    • Contact
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • 3 News in Focus
      • 5 Business & Money
      • 5 Science & Tech
      • 5 Lifestyle & Health
      • 1 Policy & Public Interest
      • 1 People & Culture
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content
      • All Products
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • General Inquiries
      • Editorial Bureaus
      • Partnerships
      • Media Inquiries
      • Worldwide Offices
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      Close submenu (News in Focus) News in Focus
      • Browse News Releases
      • Multimedia Gallery
      • Trending Topics
      Close submenu (Business & Money) Business & Money
      • Auto & Transportation
      • Business Technology
      • Entertain­ment & Media
      • Financial Services & Investing
      • General Business
      Close submenu (Science & Tech) Science & Tech
      • Consumer Technology
      • Energy & Natural Resources
      • Environ­ment
      • Heavy Industry & Manufacturing
      • Telecomm­unications
      Close submenu (Lifestyle & Health) Lifestyle & Health
      • Consumer Products & Retail
      • Entertain­ment & Media
      • Health
      • Sports
      • Travel
      Close submenu (Policy & Public Interest) Policy & Public Interest
      • Policy & Public Interest
      Close submenu (People & Culture) People & Culture
      • People & Culture

      Verenium Reports Financial Results For The Third Quarter And Nine Months Ended September 30, 2012

      -- Company strengthens balance sheet and updates 2012 financial guidance --

      Verenium Corporation

      News provided by

      Verenium Corporation

      Nov 08, 2012, 04:00 ET

      Share this article

      Share this article


      SAN DIEGO, Nov. 8, 2012 /PRNewswire/ -- Verenium Corporation (Nasdaq: VRNM), a leading industrial biotechnology company focused on the development and commercialization of high-performance enzymes, today reported operating highlights and financial results for the third quarter and nine months ended September 30, 2012.

      (Logo: http://photos.prnewswire.com/prnh/20120924/MM79973LOGO)

      "During the third quarter we made some important steps forward with our manufacturing investment program; however, the downtime experienced in manufacturing due to these upgrades combined with the continued unfavorable market conditions in corn ethanol, made this a challenging quarter financially," said James Levine, President & Chief Executive Officer at Verenium. "Despite the impact on our margins this period, we remain confident that the enhancements we are making now in our manufacturing platform, as well as our high-performance product portfolio, our current Product Pipeline and our strategy for diversifying our revenue through products for new end markets, will support our growth in the future."

      Company Highlights

      Since the beginning of 2012, the Company has made progress on both operational and financial fronts.  Recent accomplishments include:

      • Implemented manufacturing improvements that resulted in greater Fuelzyme® alpha-amylase yields and reduced manufacturing costs;
      • Presented a co-authored scientific paper reporting on our findings from research conducted with the Company's next-generation Pyrolase® HT cellulase product for breaking cross-linked fracturing fluids under extreme downhole conditions in hydraulic fracturing;
      • Ended the third quarter with unrestricted cash of $13.9 million and $4.1 million in restricted cash.

      Financial Results
      In the commentary below, the operating results of the Company's oilseed processing business, sold to DSM in March 2012, for prior periods are included in continuing operations.

      Revenues
      Revenues for the periods ended September 30, 2012 and 2011 were as follows (in thousands):


      Three Months Ended 

      September 30,


      Nine Months Ended 

      September 30,


      2012


      2011


      2012


      2011

      Revenues:








             Animal health and nutrition

      $   5,849


      $   8,624


      $  22,521


      $  24,734

             Grain processing

      2,054


      3,942


      7,895


      12,371

             Oilseed processing

      --


      1,929


      579


      4,541

             All other products

      101


      247


      972


      606

      Total product

      8,004


      14,742


      31,967


      42,252

      Contract manufacturing (1)

      1,561


      --


      4,047


      --

      Collaborative and license

      697


      3,674


      7,174


      4,694

      Total revenue

      $  10,262


      $  18,416


      $  43,188


      $  46,946


      (1)   Revenue from the DSM supply agreement is reported as contract manufacturing, revenue for Purifine and Veretase prior to the DSM transaction are reflected in oilseed processing and grain processing revenue, respectively.

      Total revenues for the nine months ended September 30, 2012 decreased 8% to $43.2 million from $46.9 million for the same period in the prior year.  Product and contract manufacturing revenues represented approximately 83% of total revenues for the nine months ended September 30, 2012 compared to 90% for the same period in the prior year.

      Product revenue for the nine months ended September 30, 2012 decreased 24% to $32.0 million from $42.3 million for the same period in the prior year, primarily due to the following:

      • A decrease in grain processing revenue compared to 2011 attributed to adverse business conditions in the corn ethanol industry, which has resulted in delays or extensions of product trials which has consequently affected new customer adoption rates and increased competitive pressure;
      • The sale and license of the Company's Purifine and Veretase products to DSM in March of 2012; and
      • A decrease in animal health and nutrition due to toll manufacturing revenue included in 2011, and lower production volumes of Phyzyme® XP phytase in the three months ended September 30, 2012 due to a shift in manufacturing to the Company's partner, Genencor, a division of DuPont, Inc.  While this shift in production has little or no impact on the gross margin in absolute dollars recognized for every sale of Phyzyme® XP, it does have a negative impact on the gross product revenue recognized for Phyzyme® XP.

      Product and contract manufacturing revenue from non-Phyzyme® XP products as a percentage of total product and contract manufacturing revenues decreased to 37% for the nine months ended September 30, 2012 compared to 50% for the same period in the prior year.  Contract manufacturing revenue increased as a result of the supply agreement entered into in conjunction with the DSM sale, under which the Company produces and sells Purifine and Veretase to DSM at lower sales prices than when the Company sold directly to end customers.

      Total collaborative revenue for the nine months ended September 30, 2012 increased to $7.2 million from $4.7 million for the same period in the prior year, primarily due to recognition of the $2.9 million license fee revenue from Novus International, Inc., and $1.5 million in license fees associated with the DSM transaction.  The Company also generated $0.5 million in revenue from a one-time up-front payment associated with the development of a commercial product under an agreement with Tate & Lyle.

      Product and Contract Manufacturing Gross Profit and Gross Margin
      Product and contract manufacturing gross profit for the nine months ended September 30, 2012 decreased 25% to $12.1 million from $16.1 million for the same period in the prior year. Gross margin decreased to 33% of total product and contract manufacturing revenue for the nine months ended September 30, 2012, compared to 38% for the nine months ended September 30, 2011.  Gross margin decreased primarily due to a shift in sales mix from higher margin grain processing revenue to the Company's lower margin supply agreement with DSM and idle capacity due to previously planned upgrades at the Company's manufacturing facility.

      Operating Expenses (excluding cost of product and contract manufacturing revenue and restructuring expense)
      Excluding cost of product and contract manufacturing revenues and restructuring charges, total operating expenses related to continuing operations for the nine months ended September 30, 2012 increased to $26.2 million (including share-based compensation of $0.7 million) from $21.7 million (including share-based compensation of $1.1 million) for the same period in the prior year.  This increase is primarily due to reimbursement of $1.1 million of legal fees during the first quarter of 2011 associated with the settlement of a noteholder lawsuit, which was recorded as an offset to operating expenses.  In addition, operating expenses were elevated during the first quarter of 2012 for transaction costs associated with various financing alternatives the Company was pursuing. Overall, after the effect of the prior year legal fee reimbursement, ongoing general and administrative expenses have remained flat over the prior year, while research and development costs have increased, reflecting continued investment in pipeline products.

      Gain on Sale of Oilseed Processing Business
      On March 23, 2012, the Company entered into an asset purchase agreement with DSM for the purchase of the Company's oilseed processing business and concurrently entered into a license agreement, a supply agreement and a transition services agreement with DSM.  The aggregate consideration received by the Company was $37 million.  The gain on sale for the nine months ended September 30, 2012 was calculated as the difference between the allocated consideration amount for the oilseed processing business, in accordance with authoritative accounting guidance, of $31.3 million and the net carrying amount of the purchased assets and liabilities and transaction costs.

      Income (Loss) from Operations
      Income from operations for the nine months ended September 30, 2012 was $24.3 million compared to loss from operations of $3.9 million for the same period in 2011, on a GAAP accounting basis.  Adjusted for the impact of restructuring expenses and the gain on sale of the oilseed business of $31.3 million, the Company's non-GAAP pro-forma loss from operations was $7.0 million for the nine months ended September 30, 2012 compared to $0.9 million for the same period in 2011.  The Company believes that excluding the impact of these items provides a more consistent measure of operating results.

      Net Income (Loss) from Continuing Operations
      Net income from continuing operations for the nine months ended September 30, 2012 was $22.4 million compared to $8.1 million for the same period in 2011, on a GAAP accounting basis. Adjusted for the impact of restructuring expenses, non-cash items related to the Company's convertible debt and gain on sale of its oilseed processing business, the Company's non-GAAP pro-forma net loss from continuing operations for the nine months ended September 30, 2012 increased to $8.1 million compared to $3.3 million for the same period in the prior year primarily due to decrease in product and contract manufacturing gross profit. The Company believes that excluding the impact of these items provides a more consistent measure of operating results. 

      Balance Sheet
      The Company ended the quarter with $13.9 million in cash and cash equivalents and $4.1 million in total restricted cash.  On October 5, 2012, the Company entered into a $10 million revolving credit facility with a maturity date of October 5, 2014.  This credit facility will allow the Company to borrow up to $8.4 million against certain eligible foreign and domestic receivables and will cover an existing $1.6 million letter of credit commitment to the Company's landlord.  The credit facility also immediately frees up $1.6 million in restricted cash which had previously secured the letter of credit.  Advances under the credit facility bear interest at a daily adjusting LIBOR plus a margin of 4.75%.  To date, the Company has not borrowed against this facility.

      Financial Guidance for 2012 

      Verenium also provided updated financial guidance for 2012, as follows:

      • Revenue: $53M- $55M
      • Product Gross Profit: $14M - $16M
      • Operating Loss: $(11)M - $(13)M (excluding gain on sale from DSM transaction)
      • Capital Expenditures: $8M - $9M

      "The revised financial guidance for 2012 we are providing today reflects the continued challenges faced by the corn ethanol industry," said Jeff Black, Chief Financial Officer at Verenium.  "Despite the decrease to our 2012 guidance we continue to execute against our financial goals in terms of decreased cash burn and operating expenses.  Importantly, the credit facility we put in place with Comerica and the equipment financing we drew down during the third quarter were two important steps in addressing our capital needs."

      About Verenium
      Verenium, an industrial biotechnology company, is a global leader in developing high-performance enzymes.  Verenium's tailored enzymes are environmentally friendly, making products and processes greener and more cost-effective for industries, including the global food and fuel markets.  Read more at www.verenium.com.

      Forward-Looking Statements
      Statements in this press release that are not strictly historical are "forward-looking" and involve a high degree of risk and uncertainty.  These include, but are not limited to, statements related to Verenium's technology, products and product candidates and product pipeline, lines of business, operations (including Verenium's ability to successfully negotiate and enter into future collaborations and partnerships), capabilities, commercialization activities, customer adoption rates, industry conditions, future financial performance, and near-term and longer-term growth and prospects.  Such statements are only predictions, and actual events or results may differ materially from those projected in such forward-looking statements.  Factors that could cause or contribute to the differences include, but are not limited to, risks associated with Verenium's strategic focus, technologies, products and product candidates and product pipeline (including Verenium's ability to identify, develop and commercialize new products and product candidates, either independently or with collaborators or partners, and market demand for those products and product candidates), dependence on patents and proprietary rights,  protection and enforcement of its patents and proprietary rights, the commercial prospects of the industries in which Verenium operates and sells products, Verenium's dependence on manufacturing and/or license agreements,  its ability to achieve milestones under existing and future collaboration agreements, the ability of Verenium and its partners to commercialize its technologies and products (including by obtaining any required regulatory approvals) using Verenium's technologies, the timing for launching any commercial products and projects, the ability of Verenium and its collaborators to market and sell any products that it or they commercialize, the development or availability of competitive products or technologies, the future ability of Verenium to enter into and/or maintain collaboration and joint venture or partnership agreements and licenses on a timely basis or at all, and risks and other uncertainties more fully described in Verenium's filings with the Securities and Exchange Commission, including, but not limited to, Verenium's annual report on Form 10-K for the year ended December 31, 2011 and any updates contained in its subsequently filed quarterly reports on Form 10-Q .  These forward-looking statements speak only as of the date hereof, and Verenium expressly disclaims any intent or obligation to update these forward-looking statements.

      Contacts:

      Sarah Carmody
      Manager, Corporate Communications
      858-431-8581
      [email protected]

      Verenium Corporation

      Condensed Consolidated Statements of Operations

      (unaudited, in thousands, except per share amounts)



      Three Months Ended

      September 30,


      Nine Months Ended

      September 30,


      2012


      2011


      2012


      2011

      Revenues:








         Product

      $  8,004


      $ 14,742


      $ 31,967


      $ 42,252

         Contract manufacturing

      1,561


      --


      4,047


      --

         Collaborative and license

      697


      3,674


      7,174


      4,694

      Total revenue

      10,262


      18,416


      43,188


      46,946









      Operating expenses:








         Cost of product and contract manufacturing revenue

      6,726


      8,698


      23,962


      26,174

      Product and contract manufacturing gross profit

      2,839


      6,044


      12,052


      16,078

      Product and contract manufacturing gross margin

      30%


      41%


      33%


      38%

         Research and development

      4,045


      2,673


      11,086


      7,593

         Selling, general and administrative

      4,783


      4,940


      15,139


      14,106

         Restructuring charges

      11


      20


      27


      2,940

      Total operating expenses

      15,565


      16,331


      50,214


      50,813









      Gain on sale of oilseed processing business

      --


      --


      31,278


      --









      Income (loss) from operations

      (5,303)


      2,085


      24,252


      (3,867)









      Other income and expense:








         Interest and other expense, net

      (78)


      (618)


      (1,130)


      (2,371)

      Gain on debt extinguishment upon repurchase of convertible notes

      --


      4,065


      --


      15,349

           Gain (loss) on net change in fair value of derivative assets and liabilities

      --


      290


      (92)


      (1,005)

      Total other income (expense), net

      (78)


      3,737


      (1,222)


      11,973









      Net income (loss) from continuing operations before income taxes

      (5,381)


      5,822


      23,030


      8,106

      Income tax benefit (provision)

      147


      --


      (595)


      --

      Net income (loss) from continuing operations

      (5,234)


      5,822


      22,435


      8,106

       Net Income (loss) from discontinued operations

      (23)


      (24)


      (49)


      37

      Net income (loss) attributed to Verenium

      $ (5,257)


      $  5,798


      $ 22,386


      $  8,143

      Net income (loss) per share, basic:

      Continuing operations

      $   (0.41)


      $   0.46


      $     1.77


      $   0.64

      Discontinued operations

      $  --


      $  --


      $  --


      $  --

      Attributed to Verenium Corporation

      $   (0.41)


      $   0.46


      $     1.77


      $   0.65

      Net income (loss) per share, diluted:

      Continuing operations

      $   (0.41)


      $   0.46


      $     1.75


      $   0.64

      Discontinued operations

      $  --


      $  --


      $  --


      $  --

      Attributed to Verenium Corporation

      $   (0.41)


      $   0.46


      $     1.74


      $  0.65









      Shares used in computing net income (loss) per share, basic

      12,765


      12,607


      12,664


      12,607

      Shares used in computing net income (loss) per share, diluted

      12,765


      12,607


      13,124


      12,607





      Verenium Corporation

      Condensed Consolidated Balance Sheet Data

      (in thousands)


      September 30,


      December 31,


      2012

      (unaudited)


      2011





      Cash and cash equivalents

      $          13,938


      $            28,759

      Restricted cash, short term

      2,500


      5,000

      Accounts receivable, net

      7,250


      11,371

      Inventories, net

      5,017


      6,323

      Other current assets 

      2,700


      2,396

      Restricted cash, long term

      1,600


      3,200

      Property and equipment, net 

      14,346


      7,806

      Other noncurrent assets 

      653


      482





      Total assets 

      $           48,004


      $           65,337









      Accounts payable and accrued expenses

      $           8,880


      $           15,062

      Other short term liabilities

      402


      436

      Deferred revenue, current 

      1,806


      4,137

      Convertible notes

      --


      34,851

      Long term debt, net of current portion

      2,705


      --

      Other long term liabilities 

      653


      906

      Stockholders' equity 

      33,558


      9,945





      Total liabilities and

          stockholders' equity 

      $          48,004


      $           65,337





      Verenium Corporation

      Unaudited Supplemental and Non-GAAP Pro Forma Financial Information

      (in thousands, except per share amounts)


      The following unaudited supplemental and non-GAAP pro forma financial information is derived from the Company's condensed consolidated financial statements for the three and nine months ended September 30, 2012 and 2011, as reported under GAAP. The Company believes that such supplemental and non-GAAP financial information is helpful to understand the results of operations of the business.


      Non-GAAP Pro Forma Income (Loss) From Operations



      Three Months Ended

      September 30,


      Nine Months Ended

      September 30,


      2012


      2011


      2012


      2011



       Income (loss) from operations

      $  (5,303)


      $   2,085


      $ 24,252


      $ (3,867)









      Adjustments: 








      Gain on sale of oilseed processing business

      --


      --


      (31,278)


      --

      Restructuring charges

      11


      20


      27


      2,940

      Non-GAAP pro forma income (loss) from operations  

      $  (5,292)


      $   2,105


      $ (6,999)


      $   (927)






      Non-GAAP Pro Forma Net Income (Loss) From Continuing Operations



      Three Months Ended

      September 30,


      Nine Months Ended

      September 30,


      2012


      2011


      2012


      2011



       Net income (loss) from continuing operations

      $  (5,234)


      $   5,822


      $  22,435


      $  8,106









      Adjustments: 








      Gain on sale of oilseed processing business.

      --


      --


      (31,278)


      --

      Restructuring charges

      11


      20


      27


      2,940

      Income tax (benefit) provision (attributed to sale of oilseed processing business)

      (147)


      --


      595


      --

      Gain on debt extinguishment upon    repurchase of convertible notes

      --


      (4,065)


      --


      (15,349)

      (Gain) loss on net change in fair value of derivative assets and liabilities

      --


      (290)


      92


      1,005

      Non-GAAP pro forma net income (loss) from continuing operations 

      $  (5,370)


      $   1,487


      $  (8,129)


      $ (3,298)

      Non-GAAP pro forma net income (loss) from continuing operations per share, basic 

      $   (0.42)


      $    0.12


      $   (0.64)


      $  (0.26)

      ­

      SOURCE Verenium Corporation

      Modal title

      Contact PR Newswire

      • Call PR Newswire at 888-776-0942
        from 8 AM - 9 PM ET
      • Chat with an Expert
      • General Inquiries
      • Editorial Bureaus
      • Partnerships
      • Media Inquiries
      • Worldwide Offices

      Products

      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content

      About

      • About PR Newswire
      • About Cision
      • Careers
      • Accessibility Statement
      • APAC
      • APAC - Simplified Chinese
      • APAC - Traditional Chinese
      • Brazil
      • Canada
      • Czech
      • Denmark
      • Finland
      • France
      • Germany
      • India
      • Indonesia
      • Israel
      • Italy
      • Japan
      • Korea
      • Mexico
      • Middle East
      • Middle East - Arabic
      • Netherlands
      • Norway
      • Poland
      • Portugal
      • Russia
      • Slovakia
      • Spain
      • Sweden
      • United Kingdom
      • Vietnam

      My Services

      • All New Releases
      • Platform Login
      • Data Privacy

      Do not sell or share my personal information:

      • Submit via [email protected] 
      • Call Privacy toll-free: 877-297-8921

      Contact PR Newswire

      Products

      About

      My Services
      • All News Releases
      • Platform Login
      • ProfNet
      Call PR Newswire at
      888-776-0942
      • Terms of Use
      • Privacy Policy
      • Information Security Policy
      • Site Map
      • RSS
      • Cookies
      Copyright © 2026 Cision US Inc.